Do you want to read an article? Please log in or register.
Molecular Determinants of Thrombosis Recurrence Risk Across Venous Thromboembolism Subtypes
Non-Malignant Blood Disorders
Related content
CHICAGO 2026
Lung, Respiratory and Thoracic Cancer
IMforte: Transcriptomic analyses support lurbinectedin plus atezolizumab maintenance across molecular subtypes in ES-SCLC
Lung, Respiratory and Thoracic Cancer
Polygenic risk score to define risk of cancer-associated thrombosis among patients with lung cancer in a population-based study
Lung Cancer
Tafur A, Sebai A, Shi Z, Wei J, Tran H, Zheng SL, Krantz S, Hensing T, Mansfield AS, Xu J
doi: 10.1016/j.lungcan.2025.108712
CHICAGO 2026
Breast Cancer
NATALEE: Gene expression analysis supports ribociclib plus NSAI across PAM50 intrinsic subtypes in HR-positive, HER2-negative early breast cancer
ELCC 2026
Lung, Respiratory and Thoracic Cancer
IMpower133/IMbrella A: Long-term survival and molecular subtype analyses with first-line atezolizumab in extensive-stage SCLC
Further Publications
Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated venous thromboembolism (API-CAT): a post-hoc analysis of a randomised, non-inferiority trial
Lancet Haematol
Mahé I, Chapelle C, Girard P, Carrier M, Palomares LJ, Samama CM, Helfer H, Gerotziafas G, Laporte S, Vicaut E, Mismetti P, API-CAT Study Group, API-CAT Investigators
doi: 10.1016/S2352-3026(25)00291-1
ESMO 2025
Genitourinary Cancer
EMBARK: Enzalutamide plus leuprolide significantly improves OS in high-risk biochemically recurrent prostate cancer
EHA 2026
Multiple Myeloma (MM)
MajesTEC-3: Teclistamab plus daratumumab maintain improved PFS and MRD negativity across high-risk multiple myeloma populations
Gynecologic Cancer
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trial
★ 3
Recommended and commented by
Dr Andreas Müller, Faculty Member
★ 1
Recommended by
Prof. Dr Beat Thürlimann, Faculty Member
Lancet Oncol
Post CCB, de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Leary A, Ottevanger PB, McCormack M, Khaw P, D'Amico R, Fyles A, Chargari C, Kitchener HC, Do V, Lissoni A, Provencher D, Genestie C, Nijman HW, Whitmarsh K, Jürgenliemk-Schulz IM, Feeney A, Lutgens LCHW, Bouma J, Leon-Castillo A, Nout RA, Putter H, Bosse T, Creutzberg CL
doi: 10.1016/S1470-2045(25)00379-1
Skin Cancer
A dynamic recurrence risk prediction tool for adjuvant therapy in stage III melanoma
Eur J Cancer
Boutros A, Taylor AM, Li I, Adegoke NA, Wong T, Varey AHR, Shannon KF, Ch'ng S, Saw RPM, Pennington T, Stretch J, Spillane A, van Akkooi ACJ, Scolyer RA, Pires da Silva I, Carlino MS, Long GV, Lo SN, Menzies AM
doi: 10.1016/j.ejca.2025.115782